NCT01829711 2020-04-08Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaMedImmune LLCPhase 3 Completed80 enrolled 32 charts 1 FDA
NCT00586924 2019-04-02A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell LeukemiaMedImmune LLCPhase 1 Completed49 enrolled 40 charts